Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16361847 | 0.81 | DRD1 (0.57) | DRD1PARP1 | |
| SCHEMBL16362111 | 0.79 | PARP1 (0.39) | PARP1SLC6A2SLC6A4HRH1SLC6A3 | |
| SCHEMBL17875572 | 0.73 | — | — | |
| SCHEMBL16362112 | 0.73 | DRD1 (0.54) | DRD1PARP1 | |
| SCHEMBL38662178 | 0.73 | DRD1 (0.56) | DRD1 | |
| SCHEMBL17875581 | 0.73 | PARP1 (0.41) | PARP1SLC6A2SLC6A4HRH1SLC6A3 | |
| SCHEMBL16362114 | 0.72 | DRD1 (0.43) | DRD1PARP1 | |
| SCHEMBL16362115 | 0.70 | MAPT (0.38) | PARP1SLC6A2SLC6A4HRH1SLC6A3 | |
| SCHEMBL16362118 | 0.68 | DRD1 (0.42) | DRD1PARP1 | |
| SCHEMBL17876422 | 0.68 | PARP1 (0.47) | PARP1SLC6A2SLC6A4HRH1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579641-B2 | Aryl phosphines with fused ring ortho-alkoxy substitution | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9579641-B2 | Aryl phosphines with fused ring ortho-alkoxy substitution | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160184811-A1 | ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160184811-A1 | ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184811-A1 | ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION | ALK, PHOSPHO1, MPL | DRD1 3012/4885PARP1 3058/4885SLC6A2 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.